Perrigo Q1 net sales $969M (-7.2%), adj EPS $0.43 (-28%); reaffirms FY 2026 outlook

PERRIGO Co plc

2026-Q1 EPS reported -$2.87 revenue$969,200,000

All In net sales $969M, down 7.2% YoY; reported diluted EPS $(2.81) due to $330.8M goodwill impairment.
Core adjusted EPS $0.40, down 20% YoY; Core organic net sales -11.0% reflecting lower seasonal cough/cold and retailer destocking.
After quarter end, completed Dermacosmetics sale for upfront cash of €306M; proceeds to support debt reduction.
Self Care segment net sales down 11.5%, operating income down 39.3% due to lower volumes and prior-year manufacturing headwinds.
Full-year 2026 outlook reaffirmed; expects second-half improvement from lapping headwinds and OEP.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PERRIGO Co plc reported the first quarter ended March 28, 2026 results: revenue $969 million, EPS $(2.81). Guidance reaffirmed.

Period: the first quarter ended March 28, 2026
Revenue: $969 million
EPS: $(2.81)
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of Women’s Health products. Core organic net sales comprised net pricing of 0.2% and volume/mix of -11.0%. • All In reported net sales declined 7.2% year over year to $969 million. The decrease was driven by the same factors impacting Core net sales, partially offset by Infant Formula net sales growth. Gross Margin • Reported gross margin was 33.6%, a

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

PERRIGO Co plc filing history →

Source: SEC EDGAR

accession 0001585364-26-000044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.